Sparks commentary

Healthcare

Sparks

FDA approves Karuna Therapeutics/Bristol Myers Squibb’s (NYSE:BMY) schizophrenia drug
Published by Arron Aatkar

The US FDA has approved KarXT, now called Cobenfy, for the treatment of schizophrenia. The drug works by a novel mechanism of action, selectively targeting muscarinic receptors M1 and M4 (associated with cognition, learning and memory) and it aims to move beyond the historic dopamine hypothesis of schizophrenia pathophysiology.

KarXT was initially developed by Karuna Therapeutics, a US-based biotechnology company. However, Karuna Therapeutics was acquired by Bristol Myers Squibb in late-2023/early-2024 in a $14bn deal primarily focused on KarXT.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free